LEXICON PHARMACEUTICALS, INC. (LXRX): restructuring charge — Lexicon cuts workforce 60%, halts commercial ops after FDA setback on ZYNQUISTA

LEXICON PHARMACEUTICALS, INC.

FDA issued 'deficiencies preclude discussion' letter for ZYNQUISTA (sotagliflozin) NDA in type 1 diabetes and CKD.
Company eliminating commercial operations and reducing workforce by approximately 60%.
Estimated pre-tax charges of $9M–$10.5M for severance and employee costs, mostly cash in Q1 2025.
Company cites need to preserve cash and focus resources on clinical development pipeline.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

LEXICON PHARMACEUTICALS, INC. announced a restructuring with charges of $9.0 million to $10.5 million affecting commercial operations and across all functions (reduce our workforce by approximately sixty percent).

Type: restructuring
Charge: $9.0 million to $10.5 million
Affected area: commercial operations and across all functions
Headcount: reduce our workforce by approximately sixty percent

Exact text from the filing

On November 22, 2024 we determined to eliminate our commercial operations and rationalize resources across all functions in order to preserve cash and focus our resources on advancing our clinical development pipeline. In connection with such determination, we intend to implement a reduction in force which will reduce our workforce by approximately sixty percent. We estimate that we will incur an aggregate of approximately $9.0 million to $10.5 million in pre-tax charges in connection with severance and other employee costs associated with the reduction in force, most of which will be paid in the first quarter of 2025 and all of which are expected to be cash expenditures.

View on SEC.gov

20 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

LEXICON PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001062822-24-000064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.